JP2011530277A - Ｅｂｖ（エプスタイン−バーウイルス）潜在性膜タンパク質（ｌｍｐ１）の細胞内領域に結合する抗体を含んでなる医薬組成物 - Google Patents

Ｅｂｖ（エプスタイン−バーウイルス）潜在性膜タンパク質（ｌｍｐ１）の細胞内領域に結合する抗体を含んでなる医薬組成物 Download PDF

Info

Publication number
JP2011530277A
JP2011530277A JP2011521593A JP2011521593A JP2011530277A JP 2011530277 A JP2011530277 A JP 2011530277A JP 2011521593 A JP2011521593 A JP 2011521593A JP 2011521593 A JP2011521593 A JP 2011521593A JP 2011530277 A JP2011530277 A JP 2011530277A
Authority
JP
Japan
Prior art keywords
lmp1
antibody
amino acid
acid sequence
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530277A5 (enExample
Inventor
岡 忠 正 大
Original Assignee
サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス）
ユニベルシテ・クロード・ベルナール・リヨン・プルミエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス）, ユニベルシテ・クロード・ベルナール・リヨン・プルミエ filed Critical サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス）
Publication of JP2011530277A publication Critical patent/JP2011530277A/ja
Publication of JP2011530277A5 publication Critical patent/JP2011530277A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011521593A 2008-08-08 2009-08-07 Ｅｂｖ（エプスタイン−バーウイルス）潜在性膜タンパク質（ｌｍｐ１）の細胞内領域に結合する抗体を含んでなる医薬組成物 Pending JP2011530277A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08162083 2008-08-08
EP08162083.3 2008-08-08
PCT/EP2009/060277 WO2010015705A1 (en) 2008-08-08 2009-08-07 Pharmaceutical compositions comprising antibodies binding to the intracellular domain of ebv (epstein-barr virus) latent membrane protein-1 (lmp1)

Publications (2)

Publication Number Publication Date
JP2011530277A true JP2011530277A (ja) 2011-12-22
JP2011530277A5 JP2011530277A5 (enExample) 2012-09-06

Family

ID=40210594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521593A Pending JP2011530277A (ja) 2008-08-08 2009-08-07 Ｅｂｖ（エプスタイン−バーウイルス）潜在性膜タンパク質（ｌｍｐ１）の細胞内領域に結合する抗体を含んでなる医薬組成物

Country Status (5)

Country Link
US (1) US20120107319A1 (enExample)
EP (1) EP2331572A1 (enExample)
JP (1) JP2011530277A (enExample)
CN (1) CN102177177A (enExample)
WO (1) WO2010015705A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012072516A1 (en) 2010-11-29 2012-06-07 Centre National De La Recherche Scientifique (Cnrs) Barf1 a diagnostic and prognostic marker for epstein-barr virus (ebv)-associated lymphoma
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
EP3494217A4 (en) 2016-08-02 2020-01-01 Dana Farber Cancer Institute, Inc. LMP1-EXPRESSING CELLS AND METHOD FOR USE THEREOF
CN111647564B (zh) * 2020-05-18 2023-07-04 李欣 抗eb病毒lmp1的单克隆抗体及其细胞株和应用
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
CN122145615A (zh) * 2026-05-07 2026-06-05 上海宏成药业有限公司 抗lmp1抗体或其抗原结合片段及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511047A (ja) * 2001-12-04 2005-04-28 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 潜伏期膜タンパク質に対する抗体およびそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511047A (ja) * 2001-12-04 2005-04-28 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 潜伏期膜タンパク質に対する抗体およびそれらの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014007968; Ｊ．　Ｉｍｍｕｎｏｌ．　Ｍｅｔｈｏｄｓ，　２００４，　Ｖｏｌ．２８７，　ｐｐ．２１-３０ *
JPN6014007969; Ｊ．　Ｃｌｉｎ．　Ｐａｔｈｏｌ．，　１９９５，　Ｖｏｌ．４８，　ｐｐ．４３８-４４２ *
JPN6014007971; Ｊ．　Ｖｉｒｏｌ．，　１９８５，　Ｖｏｌ．５５，　Ｎｏ．３，　ｐｐ．７１０-７２０ *

Also Published As

Publication number Publication date
EP2331572A1 (en) 2011-06-15
US20120107319A1 (en) 2012-05-03
CN102177177A (zh) 2011-09-07
WO2010015705A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
JP6062477B2 (ja) ヒトサイトメガロウイルス中和抗体およびその使用
ES2794088T3 (es) Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD)
ES2539751T3 (es) Anticuerpo monoclonal capaz de unirse con epítopo discontinuo específico que aparece en la región AD1 de la glucoproteína gB de citomegalovirus humano, y fragmento de unión a antígeno del mismo
JP6722233B2 (ja) 抗ｈｓｖ抗体
US11723977B2 (en) Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
KR20150002895A (ko) 인간 사이토메갈바이러스 중화 항체 및 이의 용도
CN112399975B (zh) 与Tie2结合的抗体及其用途
US20120107319A1 (en) Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1)
TWI454279B (zh) 抗單純皰疹病毒抗體及其使用方法
US20140037623A1 (en) Pharmaceutical Compositions Comprising Antibodies Binding To EBV (Ebstein-Barr Virus) Protein BARF1
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
US20170296650A1 (en) Combination of human cytomegalovirus neutralizing antibodies
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
TWI862564B (zh) 癌治療用醫藥
WO2022023292A9 (en) Corona virus spike protein-targeting antibodies and use thereof
TW202517683A (zh) 可活化之ror結合劑及其用途
TW202527984A (zh) 5t4抗體藥物結合物及其使用之方法
HK40052936A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140905